ExpreS2ion Biotech Holding AB (publ) (STO:EXPRS2)
Sweden · Delayed Price · Currency is SEK | Market Cap | 23.51M -64.2% |
| Revenue (ttm) | 24.25M +136.7% |
| Net Income | -35.91M |
| EPS | -1.51 |
| Shares Out | 23.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 307,308 |
| Open | 1.0500 |
| Previous Close | 1.0500 |
| Day's Range | 0.9000 - 1.0500 |
| 52-Week Range | 0.8800 - 19.5400 |
| Beta | 2.21 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
About STO:EXPRS2
ExpreS2ion Biotech Holding AB (publ), a clinical-stage biotechnology company, develops protein-based immunotherapies and vaccines for oncology and infectious diseases in the Nordics and internationally. The company’s lead asset is ES2B-C001, an immunotherapy candidate, which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2, as well as vaccines for Nipah virus, Malaria, and influenza. It also offers GlycoX-S2, a glyco-engineered variants of the ExpreS2 platform to modify glycosylation patt... [Read more]
Financial Performance
In 2025, STO:EXPRS2's revenue was 12.21 million, an increase of 56.00% compared to the previous year's 7.83 million. Losses were -38.09 million, 5.68% more than in 2024.
Financial StatementsNews
ExpreS2ion Biotech Holding AB Slides: 26th Annual Biotech in Europe Forum
ExpreS2ion Biotech Holding AB has posted slides in relation to its latest quarterly earnings report, which was published on October 7, 2026.
ExpreS2ion Biotech Holding AB Earnings Call Transcript: Q2 2026
Q2 2026 saw strong clinical progress for ES2B-C001, robust grant-driven financials, and a strengthened cash position following a rights issue. Phase I remains on track for end-2026 readout, with phase II planned for H2 2027 and ongoing partnering efforts supported by positive industry trends.
ExpreS2ion Biotech Holding AB Quarterly report: Q2 2026
ExpreS2ion Biotech Holding AB has published its Q2 2026 quarterly earnings report on August 20, 2026.
ExpreS2ion Biotech Holding AB Slides: Q2 2026
ExpreS2ion Biotech Holding AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 20, 2026.
ExpreS2ion Biotech Holding AB Earnings Call Transcript: Q1 2026
Q1 saw strong clinical and financial progress, with ES2B-C001 showing positive safety and immunogenicity, operating income up 132% year-over-year, and liquidity boosted by a rights issue. Multiple milestones are expected in oncology and infectious disease programs over the next year.
ExpreS2ion Biotech Holding AB Quarterly report: Q1 2026
ExpreS2ion Biotech Holding AB has published its Q1 2026 quarterly earnings report on May 28, 2026.
ExpreS2ion Biotech Holding AB Slides: Q1 2026
ExpreS2ion Biotech Holding AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 28, 2026.
ExpreS2ion Biotech Holding AB Slides: Økonomisk Ugebrev Life Science Investor Conference
ExpreS2ion Biotech Holding AB has posted slides in relation to its latest quarterly earnings report, which was published on March 25, 2026.
ExpreS2ion Biotech Holding AB Transcript: Sachs European Life Science Forum
A novel anti-HER2 breast cancer vaccine shows promising preclinical and early clinical results, with durable antibody responses and no safety concerns so far. Over the next 12–18 months, further data will guide phase II plans, leveraging a validated protein platform and strategic partnerships.
ExpreS2ion Biotech Holding AB Slides: Sachs European Life Science Forum
ExpreS2ion Biotech Holding AB has posted slides in relation to its latest quarterly earnings report, which was published on March 5, 2026.
ExpreS2ion Biotech Holding AB Earnings Call Transcript: Q4 2025
Q4 and full year 2025 saw strong clinical and financial progress, with income up 56% year-on-year and improved cost discipline. Key pipeline assets advanced, notably in oncology and infectious diseases, supported by grant funding and strategic partnerships.
ExpreS2ion Biotech Holding AB Quarterly report: Q4 2025
ExpreS2ion Biotech Holding AB has published its Q4 2025 quarterly earnings report on February 19, 2026.
ExpreS2ion Biotech Holding AB Slides: Q4 2025
ExpreS2ion Biotech Holding AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 19, 2026.
ExpreS2ion Biotech Holding AB Annual report: Q4 2025
ExpreS2ion Biotech Holding AB has published its Q4 2025 annual report on February 19, 2026.
ExpreS2ion Biotech Holding AB Earnings Call Transcript: Q3 2025
Q3 saw strong execution with increased income, improved net loss, and expanded global partnerships, including a major malaria vaccine license. Cash runway extends into Q2 2026, with key clinical and partnership milestones expected over the next 18 months.
ExpreS2ion Biotech Holding AB Quarterly report: Q3 2025
ExpreS2ion Biotech Holding AB has published its Q3 2025 quarterly earnings report on November 13, 2025.
ExpreS2ion Biotech Holding AB Slides: Q3 2025
ExpreS2ion Biotech Holding AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 13, 2025.
ExpreS2ion Biotech Holding AB Transcript: Life Science Summit 2025
A novel HER2-targeted therapeutic vaccine is advancing through phase I trials, showing promising immune responses and potential to address high unmet needs in breast cancer. The therapy targets a large, growing market and is supported by a strong pipeline, recent partnerships, and a solid financial position.
ExpreS2ion Biotech Holding AB Slides: FY 2025
ExpreS2ion Biotech Holding AB has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 13, 2025.